Editor's note: Adam Feuerstein will be the featured guest on TSC Live at noon EDT today, Sept. 29. Email your questions at firstname.lastname@example.org; tweet us on Twitter with hash tag #tsclive; or leave a message on our Facebook page. Bookmark the TSC Live page now. (Updated with Elan's SEC inquiry) THE WOODLANDS, Texas ( TheStreet) -- More bad news for Repros Therapeutics ( RPRX): The Food and Drug Administration asked the company for more clinical data on its experimental uterine fibroid drug Proellex. At the same time, regulators expressed doubts that Repros will ever be able to determine a dose of the drug that can be effective and safe. As a result, Repros said it would try to license Proellex to another company. Repros stopped clinical trials of Proellex in July and August after some patients taking the drug were diagnosed with elevated liver enzymes, a potentially dangerous side effect that could lead to permanent liver damage. Repros shares were trading around $7 this summer but have plunged to below $1 a share in recent trading.